Clinical trial NCT00980785: Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Official title: Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Alzheimer's Disease
Hypertension
Keywords: Alzheimer's Disease
Hypertension
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2009-09-21
Enrollment: 14
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's disease (AD). The purpose of the research is to see how ramipril affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord. High amounts of beta-amyloid may be associated with a greater risk of getting Alzheimer's disease. This study will see if ramipril can lower the amount of beta-amyloid in the spinal fluid. This study will also see if ramipril affects blood vessel function and memory and thinking. The investigators hope that future studies will show whether ramipril might prevent memory loss and decrease the chance of developing Alzheimer's disease.

Detailed description: High blood pressure (BP) in midlife is predictive of Alzheimer's disease (AD) in later life. Similarly, reductions in BP are associated with protection against AD. Treatment with antihypertensive medications, specifically angiotensin converting enzyme inhibitors (ACE-I) such as ramipril, is associated with up to a 55% reduction in the prevalence of AD, suggesting a potentially promising role for ACE-I in the prevention of AD. It is unknown however 1) whether ACE-Is will have the same effect on Cerebrospinal fluid (CSF) Aβ levels in humans as in animal models 2) whether ACE-Is induce changes associated with vascular function (i.e. levels of CSF angiotensin converting enzyme (ACE) and peripheral endothelial function) and 3) whether there are interactions between ACE-I-induced changes in CSF Aβ, CSF ACE and indices of vascular function.

One mechanism by which antihypertensives may protect against AD is via Aβ neuropathology. In order to better understand the mechanisms through which ACE-I may modify CSF Aβ and possibly AD risk, we propose a randomized, double-blind, placebo-controlled pilot clinical trial, enrolling 20 middle-aged (age range 40 - 65 years), mildly hypertensive (between 130 - 160 mmHg mean systolic and between 85 - 100 mmHg mean diastolic) participants, who are adult children of an individual with AD. The main objective of this trial is to examine the effects of the ACE-I, ramipril, on 1) CSF Aβ levels 2) CSF ACE levels and 3) peripheral endothelial function as measured by brachial artery flow-mediated vasodilation (FMD) and aortic augmentation index (AAIx), in middle-aged adults with mildly elevated BP, who are at increased risk of developing AD.

Eligibility criteria: Inclusion Criteria:

* Between the ages of 40 and 65
* Mean resting blood pressure between 130-160 systolic and 85-100 diastolic
* Parent with Alzheimer's Disease

Exclusion Criteria:

* Current involvement in another investigational drug trial.
* Potassium \> 5.0
* Dementia based on DSMIV criteria
* Mini-Mental State Exam (MMSE) score \< 27
* Current blood pressure medication (\< 4 months from screening)
* Weight loss medication
* Contraindications for LP
* Know diagnosis or history of hospitalization due to congestive heart failure
* Elevated creatinine (females \> 1.3 mg/dL or males \> 1.4 mg/dL at baseline)
* Diabetes Type I and II
* Know adverse reaction to an ACE-I or an angiotensin receptor blocker
* Pregnant of nursing women

Primary outcomes:
measure: Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aβ42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo
timeFrame: Baseline to 4 months
Secondary outcomes:
measure: Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo
timeFrame: Baseline to 4 months
measure: Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo
timeFrame: Baseline to 4 months
measure: Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo
timeFrame: Baseline to 4 months
Other outcomes:
Locations:
city: Madison
country: United States
facility: Wisconisn Alzheimer's Disease Research Center
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Cynthia M Carlsson, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32(1):147-56. doi: 10.3233/JAD-2012-120763.